gynecologic-cancers-2017-posters-accepted-abstracts

13 / 13

Page 65
conferenceseries.com
Volume 7, Issue 9 (Suppl) Gynecol Obstet (Sunnyvale), an open access journal
ISSN: 2161-0932 Gynecologic Cancers 2017
August 29-30, 2017
2nd International Congress on
August 29-30, 2017 | London, UK
Contemporary Issues in
Women Cancers & Gynecologic Oncology
Gynecol Obstet (Sunnyvale) 2017, 7:9 (Suppl)
DOI: 10.4172/2161-0932-C1-019
Abrikossoff tumor or granular cell tumor a rare breast tumor: About a case report
S Ayachi1, A Bachir2, A Benlaloui1, S Aoragh1, I Haddef1, A Ammari1,3, W Benbrahim1,3 and K Bouzid4,5
1Batna University, Algeria
2CHU Beni Messous, Algeria
3University of Batna, Algeria
4CHU Mustapha Algiers, Algeria
5University of Algiers, Algeria
Granular cell tumors (Abricossoff 's tumor) were described for the first time in 1926 by Abrikossoff as benign tumors. These
tumors are rare tumors, which originate from neuro ectodermic line; they can exist in many anatomical sites, but they are
most often seen in the head and neck area (in particular, the oral cavity) and then the subcutaneous tissues of the head and
neck and breasts. Breast Abrikossoff tumors pose a huge diagnosis problem because they mimic the clinical aspects of breast
cancer while it is a benign tumor, the certainty diagnosis is immune-histo-chemical. At least 50 cases of Abrikossoff malignant
tumors have been reported in the literature with metastatic lymph nodes and lung metastases which are associated with a poor
prognosis and rapidly pejorative evolutionary aspect. We report an original case of a 57-year-old patient with a right breast
tumor with synchronous bone metastases, histologic and immune-histo-chemical examination after mastectomy has shown
a granular cell tumor (PS100+, CK-). Abrikossoff tumors are rare tumors of benign reputation, this original case report is the
proof that granular cell tumors can be malignant.
Neoadjuvant chemotherapy of locally advanced cervical cancer - Ultrasound monitoring and further
surgical intervention
S L Vashakmadze1, O I Alyoshikova1, S V Ivashina1, T A Motskobili1 and L A Ashrafyan2
1Russian Scientific Center of Roentgenoradiology, Russia
2Research Center of Obstetrics, Gynecology and Perinatology named after V I Kulakov, Russia
The accumulated material from 126 patients with locally advanced cervical cancer (LACC) receiving neoadjuvant
chemotherapy (NACT) allows us to outline ways of solving the problem of monitoring the first step of treatment aimed at
identifying groups of patients who can undergo radical surgical intervention on the second step. We have set clear parameters
of NACT efficacy (2 courses under the TP scheme) by modern sonography aimed at studying the changes in tumor volume,
angioarchitectonics and velocity indices of blood flow in the uterine arteries and vessels of the cervical tumor. We developed
a working classification of vascular network of cerviсal tumor, indicating the severity of NACT effect and determined
ultrasound signs of LACC resectability (115 of 126 patients underwent operation). We conducted correlation analysis where
high diagnostic value of ultrasound in NACT is not inferior to MRI and compared the parameters of Doppler ultrasound
with drug pathomorphosis, where established high correlation. We found that the dynamics of SCC marker level should be
considered only in conjunction with more objective ultrasound parameters but not as an independent criterion of NACT
efficiency. We revealed that the decrease in cervical volume according to 3D sonography more than 30% after 1 and 50% after
2 courses indicates high sensitivity of tumor to NACT. Radical surgical intervention on the second step is feasible when tumor
volume after two courses reduced by more than 50% but not exceeding 50 cm3. For the objective solving the problem of NACT
efficiency in LACC requires the use of modern sonography.